Other Regulatory Compliance. Borrower is not subject to regulation as an "investment company" or a company "controlled" by an "investment company" within the meaning of the Investment Company Act of 1940. Borrower is not engaged principally, or as one of the important activities, in the business of extending credit for the purpose of purchasing or carrying margin stock (within the meaning of Regulations T and U of the Board of Governors of the Federal Reserve System). Borrower has complied with all the provisions of the Federal Fair Labor Standards Act.
Other Regulatory Compliance. (a) To the extent applicable to the Company Products, the Company Group is conducting and have conducted its business and operations in material compliance with the Federal Food, Drug, and Cosmetic Act (the “FD&C Act”), 21 U.S.C. §301 et. seq., and all applicable regulations promulgated by the FDA, including good clinical practices regulations and good laboratory practices regulations (collectively, “FDA Laws and Regulations”).
Other Regulatory Compliance. None of the transactions contemplated by the Transaction Documents will violate or result in a violation of Section 7 of the Exchange Act, or any regulation promulgated thereunder, including Regulations T, U and X of the Board of Governors of the Federal Reserve System.
Other Regulatory Compliance. Borrower is not required to be registered as an “investment company” or a company “controlled” by an “investment company” under the Investment Company Act of 1940, as amended. Borrower is not engaged as one of its important activities in extending credit for margin stock (under Regulations X, T and U of the Federal Reserve Board of Governors). Borrower has not violated any laws, ordinances or rules, the violation of which could reasonably be expected to have a Material Adverse Effect. Borrower has obtained all consents, approvals and authorizations of, made all declarations or filings with, and given all notices to, all Governmental Authorities that are necessary to avoid a Material Adverse Effect.
Other Regulatory Compliance. (a) Anti-Money Laundering; Counter-Terrorism Financing. To the extent required by any Governmental Authority or by applicable law of any related jurisdiction, Buyer represents and warrants that it complies with all anti-money laundering and counter-terrorism financing requirements. Any and all funds, including virtual currency or cryptocurrency, Buyer uses to purchase WUN Tokens are not derived from or related to any unlawful activities, including money laundering or terrorist financing, and Buyer will not use WUN Tokens to finance, engage in, or otherwise support any unlawful activities as may be defined by any Governmental Authority.
Other Regulatory Compliance. The Grantee will ensure that all permits, licenses, and certifications necessary to implement the project have been secured prior to construction, improvement, or acquisition of a capital asset. As may be necessary, the Grantee shall be responsible for obtaining the services of appropriately licensed professionals to comply with the applicable requirements of the Business and Professions Code including but not limited to section 6700 et seq. (Professional Engineers Act) or section 7800 et seq. (Geologists and Geophysicists Act). The Grantee is solely responsible for ensuring that the project meets all legal requirements. The Grantor will not issue construction, improvement, or acquisition funds until all permits are approved.
Other Regulatory Compliance. No Loan Party has violated in any material respect any laws, ordinances or governmental rules. Except as otherwise set forth on Schedule 4.8, each Loan Party has timely filed all required material federal, state and local tax returns and paid, or made adequate provision to pay, all material taxes, assessments, deposits and contributions owed by such Loan Party. Each Loan Party has obtained all consents, approvals and authorizations of, made all declarations or filings with, and given all notices to, all government authorities that are necessary to continue its business as currently conducted.
Other Regulatory Compliance. Neither Purchaser nor any Guarantor is an "investment company" or a company "controlled" by an "investment company" within the meaning of the Investment Company Act of 1940, as amended. Purchaser and Guarantor are not engaged principally, or as one of the important activities, in the business of extending credit for the purpose of purchasing or carrying margin stock (within the meaning of Regulations T and U of the Board of Governors of the Federal Reserve System). Purchaser and Guarantor have complied with all the provisions of the Federal Fair Labor Standards Act and the Labor Code of the Republic of Chile. Purchaser and Guarantor have not violated any statutes, laws, ordinances or rules applicable to them, violation of which would be reasonably likely to have a Material Adverse Effect.
Other Regulatory Compliance. Section 3.27(a) of the Company Disclosure Letter contains a true and correct listing of all political contributions and lobbying expenses incurred by the Company or, to the Knowledge of the Company, on its behalf (including, to the Company’s Knowledge, by any employee, director, officer, independent contractor or agent of the Company, in each case solely to the extent acting on the Company’s behalf) at any time subsequent to January 1, 2010. All such contributions and expenses were made and incurred in compliance, in all material respects, with all applicable Legal Requirements and no such contribution or expense incurred by the Company or, to the Knowledge of the Company, on its behalf (including, to the Company’s Knowledge, by any employee, director, officer, independent contractor or agent of the Company) will restrict the Company from conducting business with any Governmental Authority.
Other Regulatory Compliance. (a) To the extent the Company’s Business as currently conducted, is directly subject to the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. §301 et. seq., or the United States Public Health Service Act or the regulations promulgated thereunder, including without limitation good clinical practices, good laboratory practices and good manufacturing practices regulations and any similar foreign laws and regulations (collectively, “FDA Laws and Regulations”), the Company has complied with FDA Laws and Regulations in all material respects.
